1.915
2.05%
-0.035
Sangamo Therapeutics Inc stock is traded at $1.915, with a volume of 733.52K.
It is down -2.05% in the last 24 hours and up +109.20% over the past month.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
See More
Previous Close:
$1.95
Open:
$1.95
24h Volume:
733.52K
Relative Volume:
0.10
Market Cap:
$423.50M
Revenue:
$176.23M
Net Income/Loss:
$-257.83M
P/E Ratio:
-1.3207
EPS:
-1.45
Net Cash Flow:
$-246.00M
1W Performance:
-11.16%
1M Performance:
+109.20%
6M Performance:
+219.72%
1Y Performance:
+410.97%
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Name
Sangamo Therapeutics Inc
Sector
Industry
Phone
(510) 970-6000
Address
501 CANAL BLVD., RICHMOND, CA
Compare SGMO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
SGMO | 1.915 | 423.50M | 176.23M | -257.83M | -246.00M | -1.45 |
VRTX | 447.55 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 741.92 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 589.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.88 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 103.41 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-28-23 | Downgrade | BofA Securities | Neutral → Underperform |
Feb-27-23 | Upgrade | Wedbush | Neutral → Outperform |
Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
Jun-13-22 | Resumed | Wedbush | Neutral |
May-04-21 | Initiated | RBC Capital Mkts | Outperform |
Jan-07-21 | Resumed | Guggenheim | Neutral |
Jan-06-21 | Initiated | Stifel | Hold |
Dec-16-20 | Resumed | H.C. Wainwright | Buy |
Sep-08-20 | Initiated | BofA Securities | Buy |
Jul-07-20 | Initiated | SunTrust | Buy |
Aug-26-19 | Initiated | H.C. Wainwright | Buy |
Nov-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
Nov-09-18 | Downgrade | Guggenheim | Buy → Neutral |
Oct-10-18 | Initiated | Guggenheim | Buy |
Jun-20-18 | Initiated | BofA/Merrill | Buy |
Nov-15-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
Jun-22-17 | Resumed | Jefferies | Buy |
Nov-01-16 | Downgrade | Wedbush | Outperform → Neutral |
Oct-19-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
Dec-04-15 | Initiated | Wells Fargo | Outperform |
Oct-23-15 | Resumed | Jefferies | Buy |
May-03-13 | Initiated | BioLogic Equity Research | Sell |
Feb-23-11 | Reiterated | JMP Securities | Mkt Outperform |
Jul-29-10 | Reiterated | Wedbush | Outperform |
Oct-19-09 | Initiated | Brean Murray | Sell |
Oct-07-09 | Reiterated | Leerink Swann | Outperform |
Aug-25-09 | Reiterated | JMP Securities | Mkt Outperform |
View All
Sangamo Therapeutics Inc Stock (SGMO) Latest News
Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts - Simply Wall St
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain - BioSpace
Sangamo stock climbs 12% post-market on FDA update for ST-503 - MSN
Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment - Marketscreener.com
Sangamo's Novel Gene Therapy for Chronic Pain Gets FDA Clearance for Clinical Trials | SGMO Stock News - StockTitan
What is HC Wainwright's Forecast for SGMO FY2024 Earnings? - MarketBeat
FY2028 Earnings Forecast for SGMO Issued By HC Wainwright - MarketBeat
Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $9.00 at Barclays - MarketBeat
Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces challenges, opportunities - Investing.com Canada
Sangamo: Q3 Earnings Snapshot - Marketscreener.com
Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates - MSN
Earnings call: Sangamo Therapeutics reports progress in gene therapies By Investing.com - Investing.com Australia
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Sangamo Therapeutics reports progress in gene therapies - Investing.com India
Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
SGMOSangamo Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Sangamo Therapeutics Q3 beats propel stock 5% higher - MSN
Sangamo Therapeutics earnings beat by $0.06, revenue topped estimates - Investing.com UK
Sangamo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results - Business Wire
Sangamo Therapeutics's Earnings Outlook - Benzinga
FY2024 Earnings Forecast for SGMO Issued By HC Wainwright - Defense World
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
Equities Analysts Set Expectations for SGMO FY2024 Earnings - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Reaches New 12-Month High on Analyst Upgrade - Defense World
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - The Manila Times
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - GlobeNewswire Inc.
Sangamo (SGMO) Stock Rally Continues In Pre-Market Ahead of Financial Results Release - Stocks Telegraph
Sangamo Therapeutics (SGMO) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $10.00 at HC Wainwright - MarketBeat
Vanguard Group Inc's Strategic Reduction in Sangamo Therapeutics Inc - GuruFocus.com
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast - StockTitan
individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week - Yahoo Finance
Sangamo Therapeutics (NASDAQ:SGMO) Stock Crosses Above 200 Day Moving Average – Here’s Why - Defense World
Sangamo Therapeutics (NASDAQ:SGMO) Stock Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat
Gene Therapy Market Detailed Analysis and Forecast to 2031 - InsightAce Analytic
StockWatch: Sangamo Shares Surge on Shorter Pathway for Fabry Candidate - Genetic Engineering & Biotechnology News
Fabry disease gene therapy study data enough for FDA submission - Fabry Disease News
Prime Medicine Spat with Tessera Rumbles on at ESGCT - Genetic Engineering & Biotechnology News
Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On FridayBooz Allen Hamilton (NYSE:BAH) - Benzinga
Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads - Investing.com
Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads By Investing.com - Investing.com UK
4 Analysts Have This To Say About Sangamo Therapeutics - Benzinga
What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You - Simply Wall St
Sangamo shares jump as FDA clears faster gene therapy pathway - The Pharma Letter
Sangamo stock rallies 37% on FDA update for Fabry disease drug - MSN
Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon - Barchart
Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Traders Purchase Large Volume of Call Options on Sangamo Therapeutics (NASDAQ:SGMO) - MarketBeat
Sangamo Therapeutics Inc Stock (SGMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):